July 14, 2025

Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Clinical trial explores TP-0903 and decitabine effects on TP53 mutations in elderly AML patients, indicating potential treatment options.

Phase 1b/2 trial examines TP-0903 and decitabine in patients with untreated acute myeloid leukemia (AML).
Patients were assessed for TP53 variant allele frequency (VAF) and response rates, focusing on treatment outcomes.
The study observed VAF changes in those achieving complete response, with variations between dosage levels.
Results could influence treatment strategies for AML in elderly patients, especially those with TP53 mutations.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark